A study reporting the outcome of a high-risk group of patients treated with 78 Gy of EBRT and ADT demonstrated that GS 8–10, PSA > 20 ng/ml, and clinical stage T3 could be unfavorable parameters for bPFS and that GS was the only factor to correlate independently with cancer-specific survival [14]. The gene discussed is KLK3; the disease is cancer.